Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)

NCT03801525 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

277

Enrollment

INDUSTRY

Sponsor class

Stopped Strategic/Business decision

Conditions

Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma

Interventions

DRUG: Ublituximab
DRUG: Umbralisib
DRUG: Venetoclax

Sponsor

TG Therapeutics, Inc.